Literature DB >> 27001592

What Is the Malignancy Risk in Neurofibromatosis Type 1?

D Gareth R Evans1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27001592     DOI： 10.1200/JCO.2016.66.8186

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Recurrent vulvar melanoma in a patient with neurofibromatosis and gastrointestinal stromal tumour.

Authors:  Anna Linehan; Emily Harrold; Keith Pilson; John McCaffrey
Journal:  BMJ Case Rep       Date:  2019-01-20

2.  Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature.

Authors:  Lorena P Suarez-Kelly; Lianbo Yu; David Kline; Eric B Schneider; Doreen M Agnese; William E Carson
Journal:  Hered Cancer Clin Pract       Date:  2019-03-25       Impact factor: 2.857

3.  NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.

Authors:  Jean-Philippe Brosseau; Chung-Ping Liao; Yong Wang; Vijay Ramani; Travis Vandergriff; Michelle Lee; Amisha Patel; Kiyoshi Ariizumi; Lu Q Le
Journal:  Nat Commun       Date:  2018-11-27       Impact factor: 14.919

4.  Contralateral Breast Cancer With Multiple Primary Neoplasms in a Patient With Neurofibromatosis Type 1: A Case Report and Review of the Literature.

Authors:  Shifaz M Veettil; Jawaid Younus; Edward Yu
Journal:  Cureus       Date:  2021-03-06

5.  Laparoscopic retroperitoneal resection of the duodenal gastrointestinal stromal tumors in neurofibromatosis type 1; Case Report and literature review.

Authors:  Al-Danakh Abdullah; Safi Mohammed; Mohammed Alradhi; Xinqing Zhu; Deyong Yang
Journal:  Front Surg       Date:  2022-08-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.